Inspira™ technologies reports full year 2023 financial results

Fda submission for approval of inspira™ art100 95% accuracy results for hyla™ blood sensor compared to standard blood gas analyzers granted u.s. patent for inspira™ art medical device ra'anana, israel , march 25, 2024 /prnewswire/ -- inspira technologies oxy b.h.n. ltd. (nasdaq: iinn) (nasdaq: iinnw) (the "company" or "inspira technologies"), a breakthrough medical technology company, today announced its financial results for the year ended december 31, 2023.
IINN Ratings Summary
IINN Quant Ranking